Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Payables: 2019-2025

Historic Payables for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $1.3 million.

  • C4 Therapeutics' Payables fell 11.37% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 1.22%. This contributed to the annual value of $1.3 million for FY2024, which is 8.16% down from last year.
  • Per C4 Therapeutics' latest filing, its Payables stood at $1.3 million for Q3 2025, which was down 39.85% from $2.2 million recorded in Q2 2025.
  • C4 Therapeutics' Payables' 5-year high stood at $4.5 million during Q4 2021, with a 5-year trough of $683,000 in Q1 2025.
  • For the 3-year period, C4 Therapeutics' Payables averaged around $1.4 million, with its median value being $1.3 million (2025).
  • In the last 5 years, C4 Therapeutics' Payables slumped by 73.99% in 2022 and then soared by 142.72% in 2025.
  • Over the past 5 years, C4 Therapeutics' Payables (Quarterly) stood at $4.5 million in 2021, then plummeted by 73.99% to $1.2 million in 2022, then rose by 23.38% to $1.4 million in 2023, then declined by 8.16% to $1.3 million in 2024, then fell by 11.37% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.2 million for Q2 2025, and $683,000 during Q1 2025.